15.69
-0.72 (-4.39%)
| Previous Close | 16.41 |
| Volume | 1,005,518 |
| Price / Sales | 2.14 |
| 52 Weeks Range |
| Profit Margin | -93.04% |
| Operating Margin (TTM) | -102.62% |
| Diluted EPS (TTM) | -5.83 |
| Quarterly Revenue Growth (YOY) | 28.00% |
| Total Debt/Equity (MRQ) | 588.24% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -389.94 M |
| Levered Free Cash Flow (TTM) | -172.94 M |
| Return on Assets (TTM) | -24.51% |
| Return on Equity (TTM) | -377.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ultragenyx Pharmaceutical Inc. | Mixed | Bearish |
AIStockmoo Score
| Value 35% | -2.6 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -2.6 |
| Timing 35% | 1.7 |
| AI Technical info | NA |
| Technical Oscillators info | 0.5 |
| Technical Moving Averages info | 3.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.5% |
| Pillar Agreement | ×0.85 |
| Not in score | |
| Price Volatility info | 1.5 |
| Final Score | -0.33 |
Select this tab to load the latest available analysis.
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.20% |
| % Held by Institutions | 99.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sands Capital Management, Llc | 30 Jun 2026 | 3,158,368 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 1,717,505 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |